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Case report 1
A 79-year-old woman had previously been treated for 
breast and urothelial cancer. A contrast-enhanced CT, ac-
quired during followup, showed multiple pulmonary and 
lymph-node lesions as well as irregularly vascularized solid 
tissue inside the bladder.
A whole-body PET scan was acquired 60 minutes after 
intravenous injection of  the (18F)FDG. At the time of  the 
tracer injection, the patient had fasted for more than six 
hours, and the glucose blood level was 101 mg/dL. A sec-
ond scan of  the pelvis was acquired 30 minutes after the 
end of  the whole-body exam, that is, two hours after the 
injection. As shown in Fig. 1, the delayed acquisition made 
it possible to visualize and characterize as malignant the 
tissue inside the bladder. In fact, (18F)FDG uptake, 
semiquantified by the Standardized Uptake Value (SUV), 
increased in the lesion while the urinary activity signifi-
cantly decreased; the final result was the inversion of  the 
lesion/background ratio (see Table). Biopsy of  the tissue 
inside the bladder confirmed the presence of  urothelial 
cancer recurrence.
Case report 2
This 66-year-old woman had been previously treated for 
cervical cancer by radiochemotherapy. During followup, a 
pelvic MRI identified a 20-mm solid lesion in the uterine 
cervix. The result of  the whole-body PET scan was am-
biguous due to the closeness of  the abnormal (18F)FDG 
uptake to the bladder; thus it was impossible to distinguish 
between cervical recurrence and urinary stasis (which is 
often evident inside the distal part of  the ureter). Delayed 
acquisition, as shown in Fig. 2, made it possible to charac-
terize the abnormal pelvic finding near the bladder as 
pathological: the activity of  the lesion increased over time, 
while the urinary activity decreased (Table). In this case as 
well, the biopsy confirmed the presence of  a cancer 
recurrence.
Discussion
Today, PET with 2-deoxy-2-(18F)fluoro-D-glucose 
([18F]FDG) is an integral part of  the diagnostic workup in 
patients with suspected or confirmed cancer (1). In fact, by 
using a radiolabeled analog of  the glucose (for example, 
[18F]FDG), it is possible to study glucose metabolism that 
is overstocked in cancer cells (2). That is due to the fact that 
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Figure 1. 79-year-old woman with suspected recurrance of urothelial cancer. Transaxial images at the bladder level, CT scan, 
PET scan, and fusion. A. At one hour post injection, PET shows a “minus” inside the bladder. B. At two hours post injection, 
the tumoral lesion is clearly evidenced by greater (18F)-FDG uptake than the background.
Figure 2. 66-year-old woman previously treated for cervical cancer, with suspected recurrence. Sagittal images at the bladder 
level, CT scan, PET scan, fusion, and Maximum Intensity Projection (MIP). A. At one hour post injection, PET shows an ab-
normal (18F)-FDG close to the bladder. B. At two hours post injection, the kinetics of the abnormal uptake make it possible to 
characterize the lesion.
 
most of  the tumors overexpress glucose transporters and 
hexokinase enzymes, leading to an increase of  the glucose 
uptake over time. Furthermore, thanks to the possibility of  
matching PET functional images with CT anatomical ones, 
this kind of  study yields a very high diagnostic accuracy, 
leading to a change of  the patient management in about 
30% of  cases (3). 
However, some pitfalls limit the use of  PET in cancer 
patients; in the case of  pelvic malignancies, due to 
(18F)FDG renal excretion, focal uptake at the level of  the 
urinary tract can mimic pathological uptake, thus allowing 
false positive results (4). In order to improve PET accuracy, 
several methods have been proposed (5, 6): some authors 
have used retrograde irrigation of  the bladder (7, 8), and 
others have performed forced diuresis by injecting fu-
rosemide and acquiring PET scans immediately after. Some 
researchers have used different metabolic tracers such as 
choline and acetate, and others have used dual-phase ac-
quisition (5, 6, 9). However, each one of  these techniques 
presents some limits. The retrograde irrigation of  the blad-
der causes discomfort to the patient, increases the radiation 
exposure for the operators, and could cause infection. The 
injection of  furosemide before image acquisition does not 
guarantee accurate results, and no consensus has yet 
formed about the optimal time and the dose of  diuretic 
that should be injected. Tracers other than (18F)FDG are 
not commonly available and can be expensive; in addition, 
few are familiar with them. Dual-phase acquisition is time-
consuming and is limited by both tracer and PET tomo-
graph availability. The rationale of  delayed acquisition is 
based on the kinetic biodistribution of  (18F)FDG, which is 
different in cancer cells compared to normal ones. In fact, 
while the neoplastic tissue continues to accumulate the 
tracer over the time, the normal cell undergoes tracer 
washout. This phenomenon leads to an increase of  tumor-
to-background ratio over time, with a clear improvement of 
the lesion visualization and characterization (Table).
The kinetics of  (18F)FDG biodistribution have been ex-
tensively investigated, and the use of  delayed acquisition 
has been suggested by several authors to address different 
clinical problems. In the case of  suspected inflammatory 
lesions, we can use dual-phase acquisition: while cancer 
tissue continues to increase tracer uptake over time, in-
flammatory disease is more often charac-
terized by the stability or by the decrease 
of  the (18F)FDG uptake. In the identifica-
tion of  hepatic and peritoneal metastases, 
Arena and Penna demonstrated how de-
layed acquisition can be useful; in these 
cases, while the tumor tissue increased its 
activity over time, the background level 
tended to decrease, with a final increase in 
the lesion/background ratio (10, 11).
     In the two cases presented above, the 
increased activity of  the cancer tissue, 
together with the reduction of  the urinary 
activity, led to the detection of  two lesions 
that could not be visualized or character-
ized by standard acquisition. In our pre-
sent experience, the comparison of  de-
layed to standard acquisition is very useful, 
allowing the clear identification of  the 
lesion and clarifying its pathological na-
ture. The key observation in our paper is 
that with delayed acquisition we can ob-
serve a significant reduction in the maxi-
mum and mean activity values of  the uri-
nary system while, as expected, the neo-
plastic tissue activity continues to increase 
over time with an inversion of  the tumor/urinary back-
ground ratio (Table).
In conclusion, the dual-phase scan is a method that is 
safe and easy to perform. It does not cause excessive radia-
tion exposure for technologists or discomfort for patients. 
While it is time-consuming, the indisputable benefit for the 
patient suggests that it should be performed more fre-
quently. The ability of  an (18F)FDG-PET study to detect 
pelvic malignancies is increased by dual-phase acquisition 
due to the kinetics of  (18F)FDG in tumor tissue and to the 
significant reduction of  urinary activity during the time. 
Therefore, while clinical trials would be useful to compare 
this practice with the other methods already mentioned, 
this procedure should be encouraged in order to metaboli-
cally characterize suspect findings in the pelvic area.
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SUV Acquisition Lesion Bladder Ratio (L/Bg)
Case 1 max 1 8.5 19.3 0.440
2 15.4 8.5 1.812
mean 1 6.2 16.5 0.376
2 12.7 7.2 1.764
Case 2 max 1 13 24 0.542
2 18.9 8.8 2.148
mean 1 11.2 21.5 0.521
2 13.2 7.6 1.737
Table. (18F)-FDG uptake, semiquantified by SUVmax and SUVmean of the 
lesion and of the bladder, and ratio for the first and second acquisition, 
respectively.
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